Evidence map›Paper›PMID 34269146›Full record

ArticleBioengineered2021

MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome.

Guanzhi Liu, Yutian Lei, Sen Luo, Zhuo Huang, Chen Chen, Kunzheng Wang, Pei Yang, Xin Huang

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Guanzhi LiuBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yutian LeiBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Sen LuoBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhuo HuangBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Chen ChenDepartment of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kunzheng WangBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Pei YangBone and Joint Surgery Center, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xin HuangDepartment of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Second Affiliated Hospital of Xi'an Jiaotong University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lack of efficient biomarkers is the main reason for the inaccurate early diagnosis and poor treatment outcomes of patients with metabolic syndrome (MetS). The current study aimed to identify several novel microRNA (miRNA) biomarkers for metabolic syndrome via high-throughput sequencing and comprehensive bioinformatics analysis. Through high-throughput sequencing and differentially expressed miRNA (DEM) analysis, we first identified two upregulated and 36 downregulated DEMs in the plasma samples of patients with MetS compared to the healthy volunteers. Additionally, we also predicted 379 potential target genes and subsequently carried out enrichment analysis and protein-protein interaction network analysis to investigate the signaling pathways and functions of the identified DEMs as well as the interactions between their target genes. Furthermore, we selected two upregulated and top 10 downregulated DEMs with the highest |log2FC| values as the key microRNAs, which may serve as potential biomarkers for MetS. RT-qPCR was performed to validated these result. Finally, hsa-miR-526b-5p, hsa-miR-6516-5p was identified as the novel biomarkers for MetS.

Indexed as

Metabolic SyndromeMicroRNAsBiomarkersComputational BiologyGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansProtein Interaction MapsSequence Analysis, RNATranscriptomeBiomarkersMicroRNAsbioinformaticsbiomarkerhigh-throughput sequencingMetabolic syndromemiRNA

Identifiers

PMID34269146
PMCPMC8806888
OpenAlexW3178671047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.